NIH R01 · 2025
Vectored HIV Immunotherapy via in vivo B cell editing
ABSTRACT A variety of gene therapy strategies have been developed to achieve HIV cure. These strategies include genetic methods to render immune cells resistant to infection or to enhance immune effector cell anti-HIV activity. In this latter instance, genetic engineering of B cells has provided a highly novel means to achieve vectored immunotherapy for production of broadly neutralizing anti-HIV antibodies (bnAbs). Of note, the exceptional utilities of gene editing have been successfully employed to achieve precision genome modification of B cells to accomplish this technical end. In this approach, primary mature B cells from the periphery are modified to express HIV bnAbs as functional…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.